Biodistribution of Fluorescent Albumin Nanoparticles among Organs of Laboratory Animals after Intranasal and Peroral Administration.
absence of interferon gene expression induction
dynamics of biodistribution in organs of mice
fluorescent BSA nanoparticles
intranasal and peroral administration
nanoprecipitation
penetration in brain and intestine
stability in blood sera and saliva
Journal
Current issues in molecular biology
ISSN: 1467-3045
Titre abrégé: Curr Issues Mol Biol
Pays: Switzerland
ID NLM: 100931761
Informations de publication
Date de publication:
11 Oct 2023
11 Oct 2023
Historique:
received:
03
08
2023
revised:
02
10
2023
accepted:
05
10
2023
medline:
27
10
2023
pubmed:
27
10
2023
entrez:
27
10
2023
Statut:
epublish
Résumé
Natural, environmental and engineered nanoparticles (NP) penetrate into cells by endocytosis and induce innate immunity. The behaviour of the nanomaterials both in vitro and in vivo should be assessed. Our goal was to study protein NP stability in biological fluids and distribution in organs of animals after intranasal and oral administration. Bovine serum albumin (BSA) was labelled with the fluorescent dye RhoB and NP were fabricated by nanoprecipitation. The fluorescent protein NPwere administered intranasally and orally in laboratory-outbred mice ICR and rabbits. RhoB-BSA NP distribution in organs was detected using spectrofluorometry and fluorescent microscopy. Innate immunity was evaluated using reverse transcription with random hexanucleotide primer and subsequent real-time PCR with specific fluorescent hydrolysis probes. The labelled BSA NP were shown to remain stable in blood sera and nasopharyngeal swabs for 5 days at +37 °C. In vivo the maximal accumulation was found in the brain in 2 days posttreatment without prevalent accumulation in olfactory bulbs. For the intestine, heart and liver, the BSA NP accumulation was similar in 1 and 2 days, whereas for kidney samples even decreased after 1 day. Both intranasal and peroral administration of RhoB-BSA NP did not induce innate immunity. Thus, after intranasal or oral instillation RhoB-BSA NP were found mainly in the brain and intestine without interferon gene expression.
Identifiants
pubmed: 37886962
pii: cimb45100519
doi: 10.3390/cimb45100519
pmc: PMC10604952
doi:
Types de publication
Journal Article
Langues
eng
Pagination
8227-8238Subventions
Organisme : strategic academic leadership program 'Priority 2030' (Agreement 075-02-2021-1316, 30 Septem-ber 2021).
ID : 075-02-2021-1316
Références
Cells. 2018 Mar 23;7(4):
pubmed: 29570659
Pharm Res. 2016 Oct;33(10):2373-87
pubmed: 27299311
J Pharmacol Exp Ther. 2006 Jun;317(3):1246-53
pubmed: 16554356
Int J Mol Sci. 2022 Apr 14;23(8):
pubmed: 35457155
Int J Nanomedicine. 2018 Nov 09;13:7303-7318
pubmed: 30519016
BMC Oral Health. 2021 Dec 20;21(1):661
pubmed: 34930236
J Control Release. 2006 Sep 12;114(3):343-7
pubmed: 16876898
Schweiz Med Wochenschr. 1984 Oct 6;114(40):1359-63
pubmed: 6208604
Int J Nanomedicine. 2007;2(4):715-33
pubmed: 18203438
Chem Res Toxicol. 2020 Oct 19;33(10):2503-2514
pubmed: 32909744
Bioeng Transl Med. 2019 Sep 05;4(3):e10143
pubmed: 31572799
Nanomedicine. 2020 Nov;30:102293
pubmed: 32853784
J Drug Target. 2002 Jun;10(4):317-25
pubmed: 12164380
Int J Nanomedicine. 2018 Oct 18;13:6637-6646
pubmed: 30425479
Nat Rev Mol Cell Biol. 2018 May;19(5):313-326
pubmed: 29410531
Int J Biol Sci. 2020 Jan 1;16(4):620-632
pubmed: 32025210
Curr Opin Biotechnol. 2014 Aug;28:69-74
pubmed: 24832077
Acta Neurochir Suppl. 2010;106:359-64
pubmed: 19812977
Pharmaceutics. 2020 Jun 29;12(7):
pubmed: 32610448
Int J Nanomedicine. 2020 Apr 30;15:2999-3022
pubmed: 32431498
Int J Mol Sci. 2023 Jan 19;24(3):
pubmed: 36768330
Adv Drug Deliv Rev. 2016 Nov 15;106(Pt B):256-276
pubmed: 27496705
Toxicol Sci. 2007 Nov;100(1):303-15
pubmed: 17709331
Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2050-5
pubmed: 17267609
Curr Med Chem. 2018;25(35):4553-4586
pubmed: 29852857